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Abstract
Background: Alcohol dependence (AD) in Europe is prevalent and causes considerable health burden. Recognition
by general practitioners (GPs) and provision of or referral to treatment may contribute to reduce this burden. This
paper studied AD prevalence in varying European primary care settings and examined who received treatment.
Methods: In a cross-sectional multi-centre study in six European countries, 358 general practitioners assessed
13,003 primary care patients between January 2013 and January 2014, of which 8,476 patients were interviewed,
collecting information on socio-demographics, physical and mental problems, and on alcohol use, problems and
treatment. AD diagnoses were determined by GPs’ clinical judgement and a standardized interview. A wide
definition for AD treatment included individual and group interventions provided by different health professionals.
Descriptive as well as inferential statistics were employed.
Results: AD was prevalent among patients in European primary health care settings (8.7 %, 95 % confidence
interval (CI): 8.1-9.3 %). Treatment rates were low (22.3 % of all AD cases, 95 % CI: 19.4-25.2 %). For both prevalence
and treatment utilization, considerable country variations were observed. AD was associated with a number of
socio-economic disadvantages (e.g. higher unemployment rate) and higher physical (e.g., liver disease, hypertension)
and mental comorbidities (e.g., depression, anxiety). Liver problems, mental distress and daily amount of alcohol used
were higher among treated versus untreated male patients with AD.
Conclusion: A minority of people identified as having AD received treatment, showing heavier drinking patterns and a
higher level of co-morbidity. Different types of treatment, depending on severity of AD, should be considered.
Keywords: Alcohol dependence, Composite International Diagnostic Interview, General practitioner, Primary care,
treatment, Co-morbidity, Liver disease, Disability, Mental distress
Background
Rationale
Mortality and disease burden in Europe are considerably
impacted by alcohol use disorders and in particular alco-
hol dependence (AD) [1, 2]. The Diagnostic and Statistical
Manual of Mental Disorders (4th Edition, DSM-IV) de-
fines AD as a mental disorder [3] with marked clinically
relevant impairments and functionality constraints. Unlike
other mental disorders, AD has not only shown to be
linked to a high level of disability [4], but also to a high
level of mortality, even in young adulthood [5, 6]. Despite
the high level of mortality and disease burden associated,
the treatment rate for AD in the adult population has
been persistently low in Europe [1, 7–9]. The reasons for
the low treatment rate are variable and understudied, and
can be categorized into aspects related to the patient (e.g.
attitudes, knowledge), the treatment system (e.g., availabil-
ity, affordability, provider skills and knowledge), and to
the larger environment [10, 11].
In order to increase treatment rates, primary care phy-
sicians or general practitioners (GPs) are considered as
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pivotal [12]. However, results of an international study
including 7 European countries conducted by the World
Health Organization in primary care centres suggests
that AD recognition by GPs was low [12]. Severity of the
disorder and associated disability have been shown to be
positively associated with better recognition [12–14]. Even
if identified, most patients with AD seem to receive no
professional interventions [7], partly because the patients
do not want treatment for their conditions, and partly be-
cause of low referral rates and/or because the GPs do not
feel competent to initiate treatment themselves [15, 16].
Research questions and objectives
The broad objective was to examine the level and nature
of alcohol problems in general and AD in particular in
primary health care facilities in six European countries.
More specific objectives were threcognition of alcohol
problems by primary health care physicians, and aspects
related to interventions. In particular, the following re-
search questions were underlying this study:
 What is the 12-month prevalence of AD in primary
health care (by region and across regions), and how
do people with an AD diagnosis differ from those
without?
 What is the proportion of people with AD in
treatment or receiving other interventions for their
alcohol problems?
 What characteristics of the patient are linked to
treatment provision?
Methods
Regions
The following regions and countries were part of the
study, representing about 6.9 % of the EU population as
whole [17]: Friuli-Venezia Giulia region (Italy1), Tuscany
region (Italy2), Saxony and Berlin state (Germany),
Hungary, Latvia, Łódzkie and Podkarpackie provinces
(Poland), and Catalonia autonomous community (Spain).
Countries were selected to include each of the three proto-
typical drinking pattern traditions in Europe [7, 18, 19],
i.e., Mediterranean wine drinking cultures (Italy, Spain),
middle European beer drinking cultures (Germany), and
central and eastern-European countries with irregular
heavy drinking occasions (Hungary, Latvia, Poland). In a
second step, we drew nationally (smaller countries: Latvia,
Hungary) and regionally representative (larger countries:
Germany, Italy, Poland, and Spain) samples of primary
care practices in these countries.
Setting and participant sampling
Even though their exact role varies by country, primary
health care practices are key to health care access in
Europe. Typically, patients consult GPs for most of their
health problems and receive basic interventions includ-
ing, but not limited to prescriptions, and may be re-
ferred to specialists if needed. Sampling patients in the
primary care practices was done between January 2013
and January 2014 on a predetermined day or consecutive
days. The GPs were instructed to assess all patients aged
18 to 64 coming to their practice for a consultation in
all countries. On average, GPs assessed 15.5 (95 % confi-
dence interval (CI): 15.3-15.7) patients on a single day.
Considerable mean differences between countries (mini-
mum: 6.4 patients in Poland; maximum: 34.4 patients in
Spain) and GPs (minimum: 1 patient per day; maximum:
53 patients per day) were present.
In Hungary and Spain, all patients consenting to study
participation were assessed by their GP, and interviewed
after their consultation. In Germany, all patients leaving
their contact details with the GP after their consultation
were asked for a subsequent interview. In the remaining
countries (Italy, Latvia, and Poland), the GP assessment
was used to determine subsamples to be interviewed.
Here, risky drinkers were oversampled in order not to
miss patients with AD. This procedure was determined
a priori and sampling design was considered in all re-
spective analyses.
Variables and measurement
Details and flow of the GP assessment and the patient
interview, as well as more information on methodo-
logical aspects of this study have been published else-
where [20, 21]. Briefly, the GPs filled in a brief form for
each patient, collecting information on general health
status and alcohol consumption, AD, as well as any
known AD treatment, which the patient might receive.
The patient interview was mainly compiled of several
standardized instruments, namely the Composite Inter-
national Diagnostic Interview (CIDI) to assess DSM-IV
AD; the Kessler Psychological Distress Scale (K10) to meas-
ure degree of current generic mental distress [22, 23]; the
World Health Organization Disability Assessment Sched-
ule 2.0 (WHODAS 2.0) to measure disability [24, 25];
and a questionnaire employed in the UK alcohol treat-
ment trials to collect data on health services utilization
[26]. In addition, open questions on alcohol treatment use
and smoking were included in the questionnaire.
Both main outcome variables were derived from a
combination of the respective questions to the GP and
to the patient. As previously shown, both GPs and CIDI
had difficulties in recognizing certain AD cases [21].
Therefore, we combined both data sources in order to
determine 12-month AD prevalence rates. For the treat-
ment access variable, we gathered information from GP
assessment and patient interview as well. While GPs
only assessed psychosocial and/or pharmacological AD
interventions (exclusively accounting for 41.1 % of all
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treatment classifications), a more detailed assessment of
professional help was included in the patient interview
(exclusively accounting for 36.0 % of all treatment classi-
fications). Patients were identified as treatment seekers if
they reported having received counselling, pharmaco-
therapy, individual or group therapy from health profes-
sionals, namely GPs, psychotherapists, psychiatrists and
other specialists for alcohol problems (e.g. hepatologist,
gastroenterologist, neurologist) or medical staff (e.g., in
the emergency department) in various settings (e.g., in-
patient, outpatient, primary care practices). Overall, we
used a wide definition including group therapies led by
health professionals, but excluded professionals such as
herbalists and priests.
Statistical methods
Sample size of patients to be assessed by the GPs and to
be interviewed were determined a priori: we aimed at
minimally 2000 primary care patients being assessed by
their GPs in each country. This figure was based on ex-
pected AD prevalence rates in primary care settings and
their recognition by GPs. A given minimal prevalence of
2.5 % AD cases recognized by GPs would have resulted
in about 50 AD cases in each country, adding up to at
least 300 AD across all countries – a sufficient sample
size to detect small to medium effects with 80 % power
[27]. Because all AD cases recognized by the GPs in
addition to a random subsample of perceived low risk
drinkers and abstainers were supposed to be interviewed,
an additional number of AD cases was expected to be
identified through the CIDI, resulting in an even greater
total sample of AD cases.
In addition to descriptive statistics (all Tables and
Web Appendices), different types of regression analyses
were used to compare the impact of various influencing
variables on different outcomes. Further, t-tests were run
to compare group means of independent groups, namely
male vs. female (Table 1 & Additional file 1: Web Appen-
dix 1) and cases without treatment vs. cases with treatment
(Table 3). Logistic regression was carried out to predict
receiving treatment among all AD cases including
socio-demographic and health measures as potential
predictors (age, sex, below socio-economic average,
unemployment, current smoking, Body-Mass-Index,
hypertension, liver problems, depression, anxiety, K10
sum score, WHODAS 2.0 sum score, daily amount of
alcohol used). All statistical analyses were done taking
sampling design into consideration (for details see
[20]). To adjust for multiple testing, Bonferroni correc-
tions were used where appropiate. The analyses were
conducted using Stata 12.0 [28].
Ethical approval
Ethical approvals to carry out the study in all study sites
have been obtained from the respective Research Ethic
Boards.
– Germany: “Ethikkommission an der TU Dresden“
(Ethics committee at Dresden University of
Technology)
– Hungary: “Budapesti Corvinus Egyetem
Társadalomtudományi Kara Etikai Bizottság”
(Corvinus University of Budapest, Faculty of
Social Ethics Committee)
– Italy1 (Friuli-Venezia Giulia): “Comitato Etico
Indipendente dell'Azienda per i Servizi Sanitari 2
‘Isontina’ ” (Independent Ethics Committee of the
Company for Health Services n°2 ‘Isontina’)
– Italy2 (Tuscany): “Comitato Etico dell'Azienda Sanitaria
Firenze” (Ethical Board of Florence Health Agency)
– Latvia: “Ētikas komitejas Rīgas Austrumu klīniskās
universitātes slimnīcas Atbalsta fonds“ (Ethics
Committee of the Riga Eastern Clinical University
Hospital Support Fund)
– Poland: “Komisja Bioetyczna przy Warszawskim
Uniwersytecie Medycznym” (Bioethics Committee
at the Medical University of Warsaw)
– Spain: ”Comité Ético de Investigación Clínica.
Hospital Clínic de Barcelona” (Hospital Clinic of
Barcelona. Ethics Committee for Clinical Research)
Table 1 12-month prevalence of alcohol dependence diagnoses by sex
AD diagnosis by GP AD diagnosis by CIDIa AD diagnosis by GP or CIDIa
Male Female Total Male Female Total Male Female Total
(N = 5,461) (N = 7,542) (N = 13,003) (N = 3,715) (N = 5,383) (N = 9,098) (N = 3,449) (N = 5,027) (N = 8,476)
Percentage diagnosed % (CI) 8.7
(8.0 - 9.4)
2.5c
(2.2 - 2.9)
5.1
(4.7 - 5.5)
9.4
(8.4 - 10.3)
3.0c
(2.5 - 3.4)
5.5
(5.1 - 6.0)
14.6
(13.4 - 15.7)
4.8c
(4.2 - 5.3)
8.7
(8.1 - 9.3)
Sought and received
professional helpb % (CI)
28.6
(24.2 - 33.0)
19.6d
(13.5 - 25.8)
26.0
(22.4 - 29.7)
18.5
(14.5 - 22.5)
14.8
(9.1 - 20.4)
17.3
(14.0 - 20.6)
24.1
(20.4 - 27.8)
18.6
(13.7 - 23.5)
22.3
(19.4 - 25.2)
Note. AD = alcohol dependence. GP = general practitioner. CIDI = Composite International Diagnostic Interview. CI = 95 % confidence interval based on
standard error
aData was weighted with inverse sampling probabilities
bPercentage of diagnosed patients that sought and received professional help. Data on help seeking behaviour derived from GP assessment in the first three
columns, from interview in column four to six and a combined measure from both GP assessment and interview was used in the last three columns
cχ2-test on sex and diagnosis, all p < .001
dχ2-test on sex and treatment reception among diagnosed AD cases, p < .05
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Results
Participants and descriptive data
Overall, 358 GPs participated, while 478 GPs refused to
take part in this study (refusal rate of 56.4 %). The GPs
assessed 13,003 patients (5,461 male and 7,542 female,
on average: 15.5 patients per day), of which 8,476 patients
(3,449 male and 5,027 female) were interviewed. Of all con-
tacted patients, 17.8 % refused to be interviewed. Sample
characteristics are published elsewhere [21]. Country varia-
tions can be found in Web Additional file 2: Appendix 2.
Prevalence of alcohol dependence
Table 1 reports 12-month AD prevalence of different
ways of identification by sex and includes the respective
proportions of patients that sought and received
treatment. The AD prevalence as determined by the
GP (5.1 %, 95 % confidence interval (CI): 4.7-5.5 %,
n = 13,003) was comparable to the prevalence determined
by the CIDI (5.5 %, 95 % CI: 5.1-6.0 %, n = 9,098), but the
overlap between both was small (18.1 % (95 % CI: 15.6-
21.0 %) of all AD cases had both diagnoses). The biggest
difference associated with GP vs. CIDI diagnoses was age
(see Fig. 1; see [21] for additional differences).
Combining both GP and CIDI derived diagnoses, 8.7 %
were identified as alcohol dependent (95 % CI: 8.1-9.3 %,
n = 8,476). In all diagnostic categories, the proportion of
males was higher than the proportion of females. Consid-
erable regional variation in AD diagnoses could be
observed (see Additional file 1: Web Appendix 1). In
Italy2 (Tuscany), the lowest rate of AD cases was consist-
ently identified across different diagnostic approaches
(GP: 1.8 %, CIDI: 1.5 %, combined: 3.7 %). The largest pro-
portion of diagnoses varied by approach: most GP diagno-
ses were given in Latvia (7.7 %, 95 % CI: 6.7-8.8 %); CIDI
identified most AD cases in Spain (7.6 %, 95 % CI: 6.4-
8.7 %); the combined approach resulted in the highest
prevalence in Italy1 (11.6 %, 95 % CI: 9.0-14.2 %).
Comparison of patients with and without alcohol
dependence
Cases with a 12-month AD diagnosis, whether identi-
fied by the GP or the CIDI, differed markedly from
subjects without such a diagnosis on several socio-
demographic, behavioural, and health variables (Table 2).
Adjusted by sex and age, they were more marginalized
(odds ratio (OR) for lower socioeconomic status (SES):
2.07, 95 % CI: 1.76-2.44; for unemployment: 2.63, 95 % CI:
2.20-3.15); more likely to be a smoker (OR: 3.16, 95 % CI:
2.70-3.69); had a higher likelihood to be co-morbid both
with physical (OR for liver problems: 7.45, 95 % CI: 5.60-
9.90) and mental disorders (OR for depression 2.46, 95 %
CI: 1.95-3.09; OR for anxiety: 2.62, 95 % CI: 2.14-3.22), and
they had higher scores on the K10 scale for severe mental
distress (OR for reaching cut-off: 2.81, 95 % CI: 2.19-3.60).
The average number of days in the last 30 days when
they were unable to perform work and/or usual daily
activities was 2.6 days among people with AD (95 %
CI: 2.1-3.0), compared to the non-dependent popula-
tion with 1.3 days (95 % CI: 1.2-1.5). As expected,
people with AD in the past 12 months also had con-
siderable higher average as well as peak alcohol con-
sumption, even though some of them were abstinent
at the time of interview (see Table 2).
Help seeking
About one in four patients with a current AD diagnosis
by GP (26.0 %, 95 % CI: 22.4-29.7 %) and 17.3 % of the
patients diagnosed by CIDI (95 % CI: 14.0-20.6 %)
sought and received professional help (the proportion
for cases defined by either GP or CIDI was 22.3 %, 95 %
CI: 19.4-25.2 %). There was considerable country variation
Fig. 1 Prevalence of alcohol dependence diagnoses by GP or CIDI, stratified by age categories. Figure displaying age effect on alcohol dependence
categories. Legend: (Blue bars) Diagnosis by GP, (Red bars) Diagnosis by CIDI, (Dashed line) Regression line GP diagnosis, (Continuous line) Regression
line CIDI diagnosis
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in the prevalence of receiving treatment, ranging between
16.6 % (95 % CI: 11.0-22.3 %) in Latvia and 38.5 % in
Italy1 (95 % CI: 26.7-50.2 %) for patients diagnosed with
AD by GP or CIDI (see Additional file 1: Web Appendix
1). Of all patients receiving professional help, 59.0 % (95 %
CI: 52.5-65.5 %) received some kind of treatment in the
GP practice.
Compared to male AD patients not seeking treat-
ment, male patients receiving professional help were
older (49.0 vs. 44.5 years of age), had more liver prob-
lems (28.1 % vs. 10.9 %), were diagnosed more often
with anxiety disorders (28.0 % vs. 14.1 %), were more
likely to be over the threshold for severe mental dis-
tress (20.6 % vs. 8.2 %), had higher K10 (13.4 vs. 8.9
points on a scale ranging 0–40) and WHODAS 2.0
sum scores (18.5 vs. 12.1 points on a scale ranging
0–100), drank more pure alcohol on a daily basis if
they did not abstain (90.3 vs. 50.8 gram per day), and
had higher proportion of chronic heavy consumption
(29.9 % vs. 12.6 % with at least 100 g daily alcohol in-
take). Comparing female AD patients on the same
measures did not yield any significant differences, but all
the comparisons were in the same direction (Table 3).
The multiple logistic regression to predict receiving
treatment among all AD cases identified liver problems
(OR: 2.43, 95 % CI: 1.46-4.04), K10 sum score (OR: 1.04,
95 % CI: 1.01-1.07) and daily amount of alcohol used
(OR: 1.01, 95 % CI: 1.00-1.01) as significant predictors
(all factors with p-value < 0.01).
Out of those patients with AD (CIDI or GP, 12-
month) that had not received any treatment, 33.5 % gave
at least one reason for not doing so: The majority did
not consider their drinking and related consequences as
a problem (57.0 %, 95 % CI: 50.2-63.8 %). Other major
answering categories (multiple answers possible) were
shame and stigma (30.0 %, 95 % CI: 23.7-36.3 %), a
number of treatment-related barriers such as afford-
ability or lack of information about treatment avail-
ability (23.6 %, 95 % CI: 17.8-29.4 %) and the wish to
cope with the problem on one’s own (19.2 %, 95 %
CI: 13.8-24.6 %). For more details on reasons for not
seeking treatment in this study see [29].
Table 2 Comparison of patients without and with 12-month alcohol dependence on socio-demographic and other variables
No AD diagnosis
(N = 7,656)
AD diagnosis by GP or
CIDI (N = 820)
Odds ratioa
(95 % confidence
interval)
Regression coefficienta
(95 % confidence
interval)
Age mean (SD) 44.3 (13.1) 45.1 (13.8) 0.79 (−0.20 - 1.78)
SES – self classified % (CI) below average 20.1 (19.2 - 21.0) 33.7 (30.4 - 37.1) 2.07 (1.76 - 2.44)b
Unemployed for health or other reason % (CI) 11.8 (11.1 - 12.6) 25.2 (22.2 - 28.2) 2.63 (2.20 - 3.15)b
Smoking % (CI) 29.5 (28.5 - 30.5) 58.8 (55.4 - 62.3) 3.16 (2.70 - 3.69)b
BMI mean (SD) 26.3 (5.2) 25.9 (5.5) −0.73 (−1.12 - -0.34)b
Hypertension % (CI) 25.7 (24.7 - 26.7) 33.1 (29.8 - 36.4) 1.30 (1.09 - 1.56)
Liver problems % (CI) 1.9 (1.5 - 2.2) 13.7 (11.3 - 16.1) 7.45 (5.60 - 9.90)b
Depression % (CI) 6.9 (6.4 - 7.5) 14.2 (11.7 - 16.6) 2.46 (1.95 - 3.09)b
Anxiety % (CI) 9.1 (8.5 - 9.8) 18.7 (15.9 - 21.4) 2.62 (2.14 - 3.22)b
K10
Above cut-off for serious mental distress % (CI) 5.1 (4.6 - 5.6) 12.1 (9.8 - 14.4) 2.81 (2.19 - 3.60)b
Total score mean (SD) 6.8 (7.0) 10.5 (8.5) 4.14 (3.55 - 4.74)b
WHODAS 2.0
Number of days of inability to carry out usual
activities or work due to health condition mean (SD)
1.3 (4.6) 2.6 (6.7) 1.21 (0.74 - 1.68)b
Total score mean (SD) 8.6 (12.6) 13.7 (16.1) 5.59 (4.47 - 6.70)b
Amount of ethanol used daily (in gram)c mean (SD) 28.5 (24.7) 57.6 (57.3) 28.44 (23.23 - 33.65)b
Chronic heavy drinkingc % (CI) at least 100 g ethanol daily 2.2 (1.4 - 3.0) 15.8 (12.4 - 19.2) 7.95 (5.10 - 12.40)b
Binge drinkingc % (CI) at least 200 g ethanol at least weekly 3.4 (2.4 - 4.3) 15.9 (12.5 - 19.3) 5.34 (3.60 - 7.93)b
Note. Data was weighted with inverse sampling probabilities
AD = 12-month alcohol dependence, determined by GP & CIDI. GP = general practitioner. CIDI = Composite International Diagnostic Interview. SD = standard
deviation. SES = socioeconomic status. CI = 95 % confidence interval based on standard error. BMI = Body-Mass-Index. K10 = Kessler Psychological Distress Scale;
cut-off for severe mental distress was 21 points in a total score range from 0 – 40. WHODAS 2.0 = World Health Organization Disability Assessment
Schedule 2.0 – total score range: 0 – 100
aRegressions are adjusted by sex and age
bp significant for Bonferroni-adjusted thresholds (p < .05/16 = 0.003125)
cexcluding past-year abstainers and low-level drinkers (i.e. drunk less than 10 g pure ethanol per day) from all analyses
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Discussion
Major findings
Overall, the results confirm that AD (8.7 %; 95 % CI:
8.1-9.3 %) is prevalent in primary care settings, with a
prevalence twice as high as the prevalence in general
population studies (3.4 %, no CI but only inter quartile
range given in the original publication: 0.7-4.7 %; [30]).
The higher prevalence may be due to a number of
factors, such as different age composition, selection of
people with more acute health problems in primary
health care, or using two measures in our primary
health care settings vs. using one measure in most gen-
eral population studies (see also [20]). The latter effect
can be quantified: using only the CIDI as measure
similarly to general population surveys resulted in a
prevalence of 5.5 % (95 % CI: 5.1-6.0 %), still considerably
higher than from general population surveys, but also
lower than the prevalence derived from multiple methods.
We also found a high degree of variability in preva-
lence between regions, in the case of the two Italian
regions even within the same country. Further, we con-
firmed that the vast majority of cases did not receive
professional treatment but treatment is preferably sought
by patients with the more severe dependence, with
higher levels of alcohol use and mental as well as phys-
ical comorbidity.
Strengths and weaknesses of the study
Our response rate on the individual level with 82.2 %
was higher than in current European surveys. Many of
our findings were based on self-report and interviews,
and the potential bias, while being found relatively low
for the instruments used [23, 25, 31–33], can never be
excluded. While being representative for the regions se-
lected, we do not and cannot claim representativeness for
larger countries or even Europe. The refusal rate at the GP
level, even though being over 50 %, seems acceptable when
compared with other studies with register-based random
sampling [34, 35]. However, it cannot be excluded that the
GPs who refused have a different patient population than
Table 3 Socio-demographic and health measures of patients with 12-month alcohol dependence by treatment and sex
Male patients with AD
(N = 558)
Female patients with AD
(N = 262)
No treatment
received
(N = 423)
Treatment
received
(N = 135)
No treatment
received
(N = 214)
Treatment
received
(N = 48)
Age mean (SD) 44.5 (14.2) 49.0 (11.5)a 43.4 (14.7) 47.1 (11.3)
SES – self classified % (CI) below average 33.2 (28.6 - 37.9) 37.5 (28.9 - 46.1) 30.6 (24.3 - 37.0) 41.6 (27.1 - 56.1)
Unemployed for health or other reason % (CI) 23.5 (19.4 - 27.6) 26.4 (18.8 - 34.1) 26.4 (20.5 - 32.3) 31.5 (18.0 - 44.9)
Smoking % (CI) 59.0 (54.2 - 63.8) 69.1 (61.0 - 77.2) 53.3 (46.5 - 60.1) 54.4 (39.8 - 68.9)
BMI mean (SD) 26.3 (5.3) 26.6 (6.0) 24.8 (5.5) 25.9 (6.0)
Hypertension % (CI) 31.2 (26.7 - 35.7) 44.7 (36.0 - 53.4) 28.0 (21.9 - 34.1) 40.1 (25.6 - 54.7)
Liver problems % (CI) 10.9 (8.0 - 13.9) 28.1 (20.1 - 36.1)a 7.6 (3.9 - 11.3) 25.7 (12.8 - 38.5)
Depression % (CI) 10.5 (7.5 - 13.5) 20.6 (13.6 - 27.6) 13.1 (8.3 - 17.9) 32.5 (18.4 - 46.6)
Anxiety % (CI) 14.1 (10.8 - 17.4) 28.0 (20.0 - 35.9)a 18.3 (13.0 - 23.5) 34.4 (20.2 - 48.6)
K10
Above cut-off for serious mental distress % (CI) 8.2 (5.5 - 10.9) 20.6 (13.5 - 27.7)a 13.9 (9.1 - 18.6) 14.2 (3.2 - 25.2)
Total score mean (SD) 8.9 (7.6) 13.4 (9.3)a 11.3 (8.9) 12.7 (9.1)
WHODAS 2.0 mean (SD)
Number of days of inability to carry out usual activities
or work due to health condition
2.3 (6.4) 4.4 (9.0) 2.2 (5.7) 2.2 (6.4)
Total score 12.1 (15.4) 18.5 (19.4)a 13.0 (14.7) 17.5 (17.5)
Amount of ethanol used daily (in gram)b mean (SD) 50.8 (46.2) 90.3 (78.8)a 43.3 (48.7) 64.9 (63.4)
Chronic heavy drinkingb % (CI) at least 100 g ethanol daily 12.6 (8.5 - 16.7) 29.9 (20.2 - 39.6)a 9.3 (3.1 - 15.4) 23.1 (5.2 - 41.1)
Binge drinkingb % (CI) at least 200 g ethanol at least weekly 15.6 (11.1 - 20.2) 21.6 (12.8 - 30.4) 10.2 (3.9 - 16.6) 19.2 (2.3 - 3.6)
Note. Data was weighted with inverse sampling probabilities.
AD = 12-month alcohol dependence, determined by GP & CIDI. SD = standard deviation. SES = socioeconomic status. CI = 95 % confidence interval based on
standard error. BMI = Body-Mass-Index. K10 = Kessler Psychological Distress Scale; cut-off for severe mental distress was 21 points in a total score range
from 0 – 40. WHODAS 2.0 = World Health Organization Disability Assessment Schedule 2.0 – total score range: 0 – 100.
ap significant for Bonferroni-adjusted thresholds (p < .05/16 tests on the same sample = .003125) in Wald tests comparing AD cases with and without treatment
within sex.
bexcluding past-year abstainers and low-level drinkers (i.e. drunk less than 10 g pure ethanol per day) from all analyses
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the participants of this study. Further, the cross-sectional
design does not allow for causal inferences of the data.
The careful assessment of each patient by standar-
dised instruments and by the GP is one of the main
strengths of the study. This allowed comparisons, and
put into perspective the results of general population
studies on alcohol use disorders.
Strengths and weaknesses in relation to other studies,
discussing important differences in results
A major finding is that just one in five patients with AD
received any formal treatment. This is in line with previ-
ous research [8, 15, 36] and has relevant public health im-
plications, since the consequences of untreated AD with
respect to mortality and burden of disease are consider-
able. Further, our results confirm pre-existing knowledge,
suggesting that treated cases show higher levels of alcohol
and health problems than their untreated counterparts. In
a study by Weisner [37], problem drinkers in the general
population differed from those in treatment in a number
of socioeconomic, drinking and other variables related to
social consequences. Our study adds that health problems
are especially more prevalent among male patients receiv-
ing treatment compared to untreated male cases. For
females, this relation did not become significant, partly
because of the smaller sample size. While the most severe
cases may find their way into treatment, a larger propor-
tion of drinkers with considerable problems still remain
untreated. In this context it should be noted that almost
60 % of the patients diagnosed with AD did not consider
their drinking as problematic, which might constitute a
major reason for low treatment rates.
Conclusion
Possible explanations and implications for clinicians and
policymakers
As GPs are key to improve recognition and treatment of
AD, more efforts are needed to enhance the GPs’ cap-
acity and knowledge to identify patients in need of and
to provide the appropriate interventions. Higher recog-
nition and interventions rates for both less severe and
severe AD cases in primary care settings could contrib-
ute to reduce individual and societal harm.
Younger people with high drinking levels were less iden-
tified by GP as compared to the CIDI. While this finding
should be confirmed in further studies, there may also
be different implications for interventions. For younger
adults, a brief intervention to reduce drinking levels may
often be best suited. At this point in the life-course, there
is less physical co-morbidity, and brief interventions have
been shown to be effective in reducing drinking among
hazardous and harmful drinkers, including less severe AD
in younger adults ([38, 39]; see also [40, 41]). For older
people with AD, given the relatively high physical and
mental co-morbidity, the GP will have to decide about
formal treatment, either in the GP setting or via referral to
specialized care. One of the problems here is that stan-
dardized guidelines often recommend all or most treat-
ment to happen in specialized care, leaving to GPs only
screening, brief interventions for problem drinkers and
referral as options [42–44]. As effective treatment options
exist including pharmaco-therapeutic options [45, 46],
most AD treatment for less severe cases could in principle
be done in primary health care.
One way to implement treatment for AD in primary
health care would be to handle alcohol use similar to
blood pressure, i.e., to routinely check consumption, to
suggest options for reduction, and to intervene if certain
thresholds are crossed and behavioural alternatives were
not successful [47]. Overall, given the high disability as-
sociated with AD [4], and the high mortality compared
to other mental disorders [5], combined with the fact
that reduction of drinking levels is clearly associated
with higher survival and less disability [48, 49], there is a
strong argument for reducing the current public health
impact of AD by increasing intervention rates, including
evidence-based formal treatment. This seems possible in
primary health care, as in our study GPs demonstrated
their ability to detect cases in need for treatment.
Unanswered questions and future research
With respect to improving the treatment system by
shifting AD treatment into primary health care, we need
to better specify barriers for intervention in the current
systems. The results of research studies up to date seem
to be inconsistent, e.g., compare the Swedish results
from Stockholm [50] with the results above. This may
not be surprising as there is considerable variation
across various health care systems in their approach to
treat AD across Europe, let alone between North America
and Europe [51, 52]. What is needed is a systematic typ-
ology for treatment systems and their specific barriers
for AD treatment (see also [29]). This promises to be an
important step in increasing treatment rates and thus
reducing the burden of AD in Europe [1].
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